Testosterone Therapy Insurance Claim Denied? How to Appeal

Testosterone therapy is a cornerstone of medical treatment for transgender men and many nonbinary people. It is not experimental, not cosmetic, and not elective in the medical sense — it is evidence-based, physician-prescribed treatment for gender dysphoria (ICD-10 F64.0), a recognized medical condition under the DSM-5. If your insurance company has denied your testosterone therapy claim, you have legal rights under federal anti-discrimination law and, in many states, additional explicit statutory protections. A well-documented appeal citing these specific legal frameworks has a high rate of success.

Why Insurers Deny Testosterone Therapy Claims

Insurance denials of testosterone therapy fall into several recurring categories. The most common is a categorical exclusion: the plan excludes all gender-affirming care, including hormone therapy, as a class of non-covered benefits. This blanket exclusion is the primary target of ACA Section 1557 anti-discrimination arguments. A second common denial type involves classification of testosterone therapy as "cosmetic" or "not medically necessary" — a characterization that directly conflicts with clinical guidelines from the World Professional Association for Transgender Health (WPATH), the Endocrine Society, the American Medical Association, and the American Academy of Family Physicians, all of which recognize hormone therapy for gender dysphoria as medically necessary evidence-based treatment.

Step therapy denials require the patient to try other treatments — often treatments that have no clinical application for gender dysphoria — before the prescribed therapy. Formulary exclusions deny coverage of the specific testosterone formulation prescribed when an alternative formulation on formulary is not clinically appropriate for the patient. Self-insured ERISA plans may maintain categorical exclusions that are not directly subject to state anti-discrimination laws, requiring a different legal strategy focused on federal protections.

Testosterone is a federally approved medication routinely covered when prescribed for cisgender men diagnosed with hypogonadism (ICD-10 E29.1) or other conditions causing low testosterone. Denying the same medication for a transgender man with gender dysphoria constitutes differential treatment based on gender identity — which is the factual core of a Section 1557 discrimination argument.

How to Appeal a Denied Testosterone Therapy Claim

Step 1: Obtain the Denial and Identify the Specific Basis

Request the formal denial letter and EOB)" class="auto-link">Explanation of Benefits (EOB). The denial must state the specific reason — categorical exclusion, medical necessity determination, formulary restriction, or step therapy requirement. Request the complete Summary Plan Description (SPD) or policy document identifying where the exclusion appears. If the plan covers testosterone for any other indication (hypogonadism, delayed puberty, certain cancers), document that fact — it is essential to your Section 1557 argument.

Step 2: Gather Clinical Documentation Establishing Medical Necessity

Obtain from your prescribing physician a detailed letter of medical necessity that: states the diagnosis of gender dysphoria with ICD-10 code F64.0; explains the clinical basis for testosterone therapy per WPATH Standards of Care Version 8 (or the applicable edition); references the Endocrine Society's Clinical Practice Guidelines for Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons; describes the clinical assessment performed and the patient's informed consent process; and explains why the specific formulation prescribed (injectable testosterone cypionate, gel, or patch) is medically appropriate for this patient. This physician letter is the most important document in your appeal.

Step 3: File the Internal Appeal Citing ACA Section 1557 Explicitly

File your internal appeal within the deadline stated in your denial letter (typically 180 days for fully insured plans). In your appeal letter, explicitly cite ACA Section 1557 (42 U.S.C. §18116), which prohibits discrimination on the basis of sex — including gender identity — by health programs receiving federal financial assistance. Argue that the plan covers testosterone for cisgender men (for hypogonadism) but denies the same medication for transgender men (for gender dysphoria), and that the only difference is the patient's gender identity. This constitutes sex discrimination prohibited by Section 1557. Attach your physician's letter of medical necessity and the clinical guidelines cited.

Step 4: Invoke State Anti-Discrimination Protections

If you live in a state with explicit transgender health insurance protections — including California, Colorado, Connecticut, Illinois, Maryland, Massachusetts, New Jersey, New York, Oregon, Vermont, Washington, and others — file a complaint with your state insurance department simultaneously. State insurance commissioners in these states have authority to enforce non-discrimination requirements for fully insured state-regulated plans. Self-insured ERISA plans are generally exempt from state law but remain subject to Section 1557 if they receive federal financial assistance.

Step 5: File a Section 1557 Complaint With the HHS OCR

File a discrimination complaint with the US Department of Health and Human Services Office for Civil Rights (OCR) at hhs.gov/ocr. The OCR enforces Section 1557 and can investigate complaints against health insurers and health programs that receive federal financial assistance. An active OCR complaint creates significant pressure on insurers to reconsider categorical gender-affirming care exclusions.

Step 6: Request External Independent Review: Complete Guide" class="auto-link">External Review and Consider Legal Action

After exhausting internal appeal options, request independent external review under your state's external review statute or under the ACA's external review requirements. External review organizations are required to apply current clinical standards — including WPATH Standards of Care — rather than the plan's internal coverage criteria. For high-value denials or systematic exclusions affecting ongoing treatment, consult an attorney experienced in Section 1557 enforcement or transgender healthcare access litigation.

What to Include in Your Appeal

• Denial letter and EOB identifying the specific exclusion or denial reason
• Physician letter of medical necessity citing ICD-10 F64.0, WPATH Standards of Care Version 8, and Endocrine Society guidelines
• Documentation that the plan covers testosterone for other indications (hypogonadism or other covered uses)
• Summary Plan Description showing the categorical exclusion language being challenged
• ACA Section 1557 and applicable state anti-discrimination statute citations
• DSM-5 diagnostic criteria for gender dysphoria supporting the medical necessity determination

Fight Back With ClaimBack

Testosterone therapy denials based on categorical gender-affirming care exclusions or medical necessity misclassifications can be overturned with an appeal that directly cites ACA Section 1557, WPATH Standards of Care, and your state's non-discrimination protections. ClaimBack generates a professional appeal letter in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal